Cargando…
Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy
BACKGROUND: A high hepatitis B virus (HBV) load is a common exclusion criterion in hepatocellular carcinoma (HCC) clinical trials for anti-programmed cell death (PD)-1 immunotherapy. However, the validity of this criterion is barely verified. This study aimed to evaluate the impact of baseline HBV D...
Autores principales: | Sun, Xuqi, Hu, Dandan, Yang, Zhoutian, Liu, Zheng, Wang, Juncheng, Chen, Jinbin, Xu, Li, Zhou, Zhongguo, Chen, Minshan, Zhang, Yaojun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718972/ https://www.ncbi.nlm.nih.gov/pubmed/33294424 http://dx.doi.org/10.2147/JHC.S278527 |
Ejemplares similares
-
Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria
por: Sun, Xuqi, et al.
Publicado: (2021) -
An integrated strategy for deciding open versus laparoscopic hepatectomy for resectable primary liver cancer
por: Fu, Yizhen, et al.
Publicado: (2023) -
Expression of hepatitis B surface antigen in liver tissues can serve as a predictor of prognosis for hepatitis B virus-related hepatocellular carcinoma patients after liver resection
por: He, Ziming, et al.
Publicado: (2020) -
Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization
por: ZHOU, DONGSHENG, et al.
Publicado: (2016) -
Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy
por: Wu, Tianqing, et al.
Publicado: (2023)